HC Wainwright Issues Negative Outlook for Indivior Earnings

Indivior PLC (NASDAQ:INDV) – Stock analysts at HC Wainwright dropped their Q1 2026 EPS estimates for Indivior in a research note issued on Friday, February 27th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.67 per share for the quarter, down from their prior estimate of $0.72. HC Wainwright currently has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s Q4 2026 earnings at $0.84 EPS and FY2030 earnings at $3.78 EPS.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million during the quarter, compared to analysts’ expectations of $305.62 million.

Several other analysts have also recently weighed in on INDV. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Morgan Stanley reiterated an “overweight” rating and set a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Finally, Northland Securities set a $50.00 price target on shares of Indivior in a research note on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Indivior presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Indivior Stock Down 2.9%

Shares of INDV opened at $32.72 on Monday. The stock has a market cap of $4.09 billion, a PE ratio of 19.95 and a beta of 0.83. Indivior has a 12-month low of $8.34 and a 12-month high of $38.00. The business has a 50-day simple moving average of $34.55 and a two-hundred day simple moving average of $30.09.

Insider Buying and Selling at Indivior

In other Indivior news, Director Barbara Ryan purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director owned 1,963 shares in the company, valued at approximately $69,470.57. The trade was a 65.24% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Keith Humphreys acquired 775 shares of the stock in a transaction dated Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director owned 5,802 shares in the company, valued at approximately $205,332.78. This represents a 15.42% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 4,871 shares of company stock valued at $172,385.

Hedge Funds Weigh In On Indivior

Several institutional investors have recently added to or reduced their stakes in INDV. Salomon & Ludwin LLC bought a new position in shares of Indivior during the 4th quarter worth approximately $30,000. Harbor Capital Advisors Inc. grew its holdings in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the period. CWM LLC bought a new stake in Indivior in the third quarter valued at $25,000. Quarry LP acquired a new position in shares of Indivior during the third quarter valued at about $26,000. Finally, GAMMA Investing LLC boosted its position in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares in the last quarter. 60.33% of the stock is owned by institutional investors and hedge funds.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.